Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0154251 (lipid disorder)
 795 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Familial combined hyperlipidemia (FCHL) is the most common genetic lipid disorder among young survivors of myocardial infarction. Elevations of plasma total and low-density lipoprotein (LDL) cholesterol and the prevalence of small, dense LDL particles are both involved in the high coronary risk of FCHL patients. We investigated the ability of pravastatin to favorably correct plasma lipid and lipoprotein levels and LDL structure in FCHL patients. Twelve patients with FCHL, documented by studies of first-degree relatives, received pravastatin (40 mg/d) for 12 weeks. Pravastatin significantly lowered plasma total and LDL cholesterol levels by 21% and 32%, respectively. Triglyceride levels did not change, and apolipoprotein B (apoB) concentrations decreased by 9% (P = NS). High-density lipoprotein (HDL) cholesterol increased by 6% because of a significant 73% rise of HDL2 cholesterol. LDL were smaller (diameter, 24.5 +/- 0.5 nm), less buoyant, and apoB-rich (cholesteryl ester-apoB ratio, 1.64 +/- 0.46) in the selected patients compared with patients with familial hypercholesterolemia or healthy control subjects. LDL became even smaller (23.8 +/- 0.6 nm) and richer in apoB (cholesteryl ester-apoB ratio, 1.27 +/- 0.52) after pravastatin treatment. Although pravastatin favorably altered plasma lipid and lipoprotein levels in FCHL patients, the abnormal LDL particle distribution and composition were not affected. Because of the apparent resistance of the small, dense LDL to drug-induced modifications, a maximal lipid-lowering effect is needed to reduce coronary risk in FCHL patients.
 ...
PMID:Pravastatin effectively lowers LDL cholesterol in familial combined hyperlipidemia without changing LDL subclass pattern. 791 6

More than 26 million prescriptions for cholesterol-lowering drugs were dispensed in the United States in 1992. These drugs represented 3.7 percent of the total pharmaceutical sales market, with retail costs exceeding $1.5 billion. Since 1988 both the number of doctor visits for disorders of lipid metabolism and the total number of prescriptions for cholesterol-lowering drugs have steadily increased. Mevacor and Lopid continue their market dominance of such drugs and accounted for almost 76 percent of the total number of 1992 cholesterol-reducing drug prescriptions dispensed. The rate of new prescriptions for cholesterol-lowering drugs was 65.1 per 1,000 population across the country; the highest rate was reported in the East North Central area and the lowest in the Pacific states. Among all specialists, general or primary care internists, family and general practice physicians and cardiologists were the most frequent prescribers of cholesterol-lowering drugs.
 ...
PMID:Use of cholesterol-lowering drugs United States, 1992. 826 79